Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA

Wendy Bannister(The Royal Free Hospital), Jens Lundgren(Centre of Excellence for Health, Immunity and Infections), Bonaventura Clotet(Universitat de Vic - Universitat Central de Catalunya), Clive Loveday(Middlesex Hospital), Schlomo Staszewski(National Institute of Allergy and Infectious Diseases), Amanda Mocroft(University of Copenhagen), Antonella d’Arminio Monforte(University of Milan), Anders Karlsson(Karolinska University Hospital), Lı́dia Ruiz(IrsiCaixa), Alessandro Cozzi‐Lepri(UCL Australia), Ole Kirk(University of Copenhagen)
AIDS
January 30, 2008
10.1097/qad.0b013e3282f3cc35
Cited by 48

Related Papers

Industrial enzyme applications
|Current Opinion in Biotechnology|2002|1.5k
Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
|JAMA|2016|1.4k
Decline in the AIDS and death rates in the EuroSIDA study: an observational study
|The Lancet|2003|1.2k
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
|AIDS|2003|987